3. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-14 discussion 14-5. PMID:
17049716
5. Irwin DE, Milsom I, Kopp Z, Abrams P, Artibani W, Herschorn S. Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. Eur Urol 2009;56:14-20. PMID:
19278775
11. Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association between polypharmacy and death: a systematic review and meta-analysis. J Am Pharm Assoc (2003) 2017;57:729-38.e10. PMID:
28784299
12. Zia A, Kamaruzzaman SB, Tan MP. Polypharmacy and falls in older people: balancing evidence-based medicine against falls risk. Postgrad Med 2015;127:330-7. PMID:
25539567
15. van den Akker M, Buntinx F, Metsemakers JF, Roos S, Knottnerus JA. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol 1998;51:367-75. PMID:
9619963
16. Wehling M. Multimorbidity and polypharmacy: how to reduce the harmful drug load and yet add needed drugs in the elderly? Proposal of a new drug classification: fit for the aged. J Am Geriatr Soc 2009;57:560-1. PMID:
19278399
17. Muderrisoglu AE, Becher KF, Madersbacher S, Michel MC. Cognitive and mood side effects of lower urinary tract medication. Expert Opin Drug Saf 2019;18:915-23. PMID:
31373245
18. Oelke M, Gericke A, Michel MC. Cardiovascular and ocular safety of alpha1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. Expert Opin Drug Saf 2014;13:1187-97. PMID:
25073735
19. Duan Y, Grady JJ, Albertsen PC, Helen Wu Z. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Pharmacoepidemiol Drug Saf 2018;27:340-8. PMID:
29316005
20. Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int 2006;97 Suppl 2:34-8 discussion 44-5. PMID:
16507052
22. Andrade C. How to read a research paper: an exercise in critical thinking in the context of an epidemiologic study on tamsulosin and the risk of dementia. J Clin Psychiatry 2018;79:18f12660.
23. Rouquier L, Claustre Y, Benavides J. Alpha 1-adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study. Eur J Pharmacol 1994;261:59-64. PMID:
8001654
25. Yamada S, Okura T, Kimura R. In vivo demonstration of alpha(1A)-adrenoceptor subtype selectivity of KMD-3213 in rat tissues. J Pharmacol Exp Ther 2001;296:160-7. PMID:
11123376
26. Yamada S, Ohkura T, Deguchi Y, Kimura R. In vivo measurement by [3H]Tamsulosin of alpha1 adrenoceptors in rat tissues in relation to the pharmacokinetics. J Pharmacol Exp Ther 1999;289:1575-83. PMID:
10336555
27. Okura T, Yamada S, Abe Y, Kimura R. Selective and sustained occupancy of prostatic α1‐adrenoceptors by oral administration of KMD‐3213 and its plasma concentration in rats. J Pharm Pharmacol 2002;54:975-82. PMID:
12162717
29. Grimes DA, Schulz KF. Bias and causal associations in observational research. Lancet 2002;359:248-52. PMID:
11812579
30. Madersbacher S, Michel MC. Re: Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Eur Urol 2018;74:522-3. PMID:
30057132
31. Tae BS, Jeon BJ, Choi H, Cheon J, Park JY, Bae JH. α-Blocker and risk of dementia in patients with benign prostatic hyperplasia: a nationwide population based study using the national health insurance service database. J Urol 2019;202:362-8. PMID:
30840545
32. Coelho BP, Gaelzer MM, Dos Santos Petry F, Hoppe JB, Trindade VMT, Salbego CG, et al. Dual effect of doxazosin: anticancer activity on SH-SY5Y neuroblastoma cells and neuroprotection on an in vitro model of Alzheimer’s disease. Neuroscience 2019;404:314-25. PMID:
30771511
33. Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 2011;108:388-94. PMID:
21631695
36. Mendell AL, Creighton SD, Wilson HA, Jardine KH, Isaacs L, Winters BD, et al. Inhibition of 5α reductase impairs cognitive performance, alters dendritic morphology and increases tau phosphorylation in the hippocampus of male 3xTg-AD mice. Neuroscience 2020;429:185-202. PMID:
31954826
38. Resnick SM, Matsumoto AM, Stephens-Shields AJ, Ellenberg SS, Gill TM, Shumaker SA, et al. Testosterone treatment and cognitive function in older men with low testosterone and age-associated memory impairment. JAMA 2017;317:717-27.
39. Welk B, McArthur E, Ordon M, Morrow SA, Hayward J, Dixon S. The risk of dementia with the use of 5 alpha reductase inhibitors. J Neurol Sci 2017;379:109-11. PMID:
28716218
40. Corkin S. Acetylcholine, aging and Alzheimer’s disease: implications for treatment. Trends Neurosci 1981;4:287-90.
41. Pavia J, De Ceballos M, de la Cuesta FS. Alzheimer’s disease: relationship between muscarinic cholinergic receptors, β‐amyloid and tau proteins. Fundam Clin Pharmacol 1998;12:473-81. PMID:
9794144
42. Quirion R, Aubert I, Lapchak P, Schaum R, Teolis S, Gauthier S, et al. Muscarinic receptor subtypes in human neurodegenerative disorders: focus on Alzheimer’s disease. Trends Pharmacol Sci 1989;Suppl:80-4. PMID:
2694529
43. Avery EE, Baker LD, Asthana S. Potential role of muscarinic agonists in Alzheimer’s disease. Drugs Aging 1997;11:450-9. PMID:
9413702
44. Yamamoto S, Maruyama S, Ito Y, Kawamata M, Nishiyama S, Ohba H, et al. Effect of oxybutynin and imidafenacin on central muscarinic receptor occupancy and cognitive function: a monkey PET study with [11C](+) 3-MPB. Neuroimage 2011;58:1-9. PMID:
21712096
48. Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D’Angelo K. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998;46:8-13. PMID:
9434659
50. Wagg A, Dale M, Tretter R, Stow B, Compion G. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol 2013;64:74-81. PMID:
23332882
51. van de Waterbeemd H, Camenisch G, Folkers G, Chretien JR, Raevsky OA. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target 1998;6:151-65. PMID:
9886238
52. Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 2000;43:3714-7. PMID:
11020286
54. Liu X, Chen C, Smith BJ. Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther 2008;325:349-56. PMID:
18203948
56. Maruyama S, Tsukada H, Nishiyama S, Kakiuchi T, Fukumoto D, Oku N, et al. In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment. J Pharmacol Exp Ther 2008;325:774-81. PMID:
18326811
57. Yoshida A, Maruyama S, Fukumoto D, Tsukada H, Ito Y, Yamada S. Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography. Life Sci 2010;87:175-80.
59. Miyamae K, Yoshida M, Murakami S, Iwashita H, Ohtani M, Masunaga K, et al. Pharmacological effects of darifenacin on human isolated urinary bladder. Pharmacology 2003;69:205-11. PMID:
14624061
60. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005;173:493-8. PMID:
15643227
61. Ikeda M, Nozawa K. Prevalence of overactive bladder and its related factors in Japanese patients with diabetes mellitus. Endocrine J 2015;62:847-54.
62. Wesnes KA, Edgar C, Tretter RN, Bolodeoku J. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf 2009;8:615-26. PMID:
19747069
64. Schwantes U, Topfmeier P. Importance of pharmacological and physicochemical properties for tolerance of antimuscarinic drugs in the treatment of detrusor instability and detrusor hyperreflexia--chances for improvement of therapy. Int J Clin Pharmacol Ther 1999;37:209-18. PMID:
10363619
65. Esin E, Ergen A, Cankurtaran M, Yavuz BB, Halil M, Ulger Z, et al. Influence of antimuscarinic therapy on cognitive functions and quality of life in geriatric patients treated for overactive bladder. Aging Mental Health 2015;19:217-23. PMID:
25555041
66. Cornu JN, Haab F. Traitements pharmacologiques de l’hyperactivité vésicale idiopathique: revue de la littérature [Pharmacological treatment of idiopathic overactive bladder: a literature review]. Prog Urol 2013;23:227-36 French. PMID:
23544979
67. Kerdraon J, Robain G, Jeandel C, Mongiat Artus P, Gamé X, Fatton B, et al. Traitement anticholinergique de l’hyperactivité vésicale de la personne âgée et ses impacts sur la cognition. Revue de la littérature [Impact on cognitive function of anticholinergic drugs used for the treatment of overactive bladder in the elderly]. Prog Urol 2014;24:672-81 French. PMID:
25214448
68. Dubeau CE, Kraus SR, Griebling TL, Newman DK, Wyman JF, Johnson TM 2nd, et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. J Urol 2014;191:395-404. PMID:
23973522
69. Sakakibara R, Hamano H, Yagi H. Cognitive safety and overall tolerability of imidafenacin in clinical use: a long-term, open-label, post-marketing surveillance study. Low Urin Tract Symptoms 2014;6:138-44. PMID:
26663594
70. Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, et al. Molecular characterization of the human beta 3-adrenergic receptor. Science 1989;245:1118-21. PMID:
2570461
71. Berkowitz DE, Nardone NA, Smiley RM, Price DT, Kreutter DK, Fremeau RT, et al. Distribution of β3-adrenoceptor mRNA in human tissues. Eur J Pharmacol 1995;289:223-8. PMID:
7621895
72. Fujimura T, Tamura K, Tsutsumi T, Yamamoto T, Nakamura K, Koibuchi Y, et al. Expression and possible functional role of the beta 3-adrenoceptor in human and rat detrusor muscle. J Urol 1999;161:680-5. PMID:
9915482
74. Kaidoh K, Igawa Y, Takeda H, Yamazaki Y, Akahane S, Miyata H, et al. Effects of selective beta2 and beta3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. J Urol 2002;168:1247-52. PMID:
12187276
75. Woods M, Carson N, Norton NW, Sheldon JH, Argentieri TM. Efficacy of the beta3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat. J Urol 2001;166:1142-7. PMID:
11490313
76. Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4’- [74] acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 2007;321:642-7. PMID:
17293563
77. Chapple CR, Siddiqui E. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia. Expert Rev Clin Pharmacol 2017;10:131-51. PMID:
28001447
78. Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodynam 2014;33:17-30.
80. Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 2013;82:313-20. PMID:
23769122
81. Chapple CR, Amarenco G, López Aramburu MA, Everaert K, Liehne J, Lucas M, et al. A proof‐of‐concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodynam 2013;32:1116-22.
82. Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013;189:1388-95. PMID:
23079373
84. Wagg A, Staskin D, Engel E, Herschorn S, Kristy RM, Schermer CR. Efficacy, safety, and tolerability of mirabegron in patients aged >/=65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol 2020;77:211-20. PMID:
31733990
85. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-9. PMID:
15817019